Biotherapharma_logo.jpg
Biothera Pharmaceuticals’ Phase 2 Study of Imprime PGG Combination Therapy in Non-Small Cell Lung Cancer Patients Published in Investigational New Drugs
March 24, 2017 10:00 ET | Biothera Pharmaceuticals, Inc.
EAGAN, Minn., March 24, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced peer-reviewed publication of results of a randomized Phase 2 clinical study of the Company’s cancer...
Biotherapharma_logo.jpg
Biothera Pharmaceuticals Announces Presentation of Clinical Data Supporting Use of a Patient Selection Biomarker for its Phase 2 Cancer Immunotherapy
February 24, 2017 14:24 ET | Biothera Pharmaceuticals, Inc.
EAGAN, Minn., Feb. 24, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. will present data today from all cohorts (total N=36) enrolled in a healthy human volunteer study of Imprime PGG, the...
Biotherapharma_logo.jpg
Biothera Pharmaceuticals Initiates Patient Dosing in Phase 2 Trial Investigating Imprime PGG and Merck’s KEYTRUDA® (pembrolizumab)
February 23, 2017 09:00 ET | Biothera Pharmaceuticals, Inc.
EAGAN, Minn., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced that dosing has been initiated in a Phase 2 clinical trial evaluating Biothera’s Imprime PGG in...
Biotherapharma_logo.jpg
Biothera Pharmaceuticals and Merck Further Expand Research Collaboration to Include Phase 2 Clinical Trial in Head and Neck Cancer
December 05, 2016 09:30 ET | Biothera Pharmaceuticals, Inc.
EAGAN, Minn., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced an expansion of its research collaboration with Merck (known as MSD outside the United States and...
SBT_New August 2022 LOGO
Fluidigm Introduces High-Parameter Maxpar Mass Cytometry Panels for Immuno-Oncology Research
November 10, 2016 08:30 ET | Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the introduction of a modular set of high-parameter Maxpar® mass cytometry...
SBT_New August 2022 LOGO
Fluidigm Announces New Customer Inspiration Center in Canada for Mass Cytometry
June 09, 2016 09:00 ET | Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., June 09, 2016 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the opening of a new customer inspiration center in Markham, Ontario, Canada....
SBT_New August 2022 LOGO
Fluidigm Announces New Integrated Fluidic Circuits for Single-Cell Genomics on the C1 System
April 12, 2016 08:43 ET | Standard BioTools Inc.
SOUTH SAN FRANCISCO, Calif., April 12, 2016 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced new integrated fluidic circuits (IFCs) that will increase the number of single...
Qu Biologics Enrolls First Two Participants in Phase 2a Clinical Trial for Lung Cancer
February 04, 2015 10:05 ET | Qu Biologics;BC Cancer Agency
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 4, 2015) - Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body's...